Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Recently it has been documented that vitamin D has important functions in the human body that are unrelated to its primary effects in calcium homeostasis and bone mineralization. In clinical studies, paricalcitol - a low-calcemic vitamin D analogue - has been shown to decrease proteinuria, a marker of disease progression and cardiovascular risk in patients with chronic kidney disease (CKD). The purpose of this study is to investigate the effect of a paricalcitol on renal and cardiovascular variables in patients with moderate to severe CKD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erling Bjerregaard Pedersen
• Treatments: Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Kidney disease corresponding to eGFR: 15-59 ml/min

• Albuminuria > 30 mg/l

Exclusion Criteria:

• Total parathyroidectomy

• Diabetes Mellitus

• Cancer

• Illicit drug or alcohol abuse

• Pregnancy og nursing

• Ongoing NSAID or corticosteroid treatment

• b-hemoglobin < 6 mmol/l

• p-albumin < 25 mmol/l

• Clinically significant hypercalcemia

• Office blood pressure > 170/105 mmHg that despite antihypertensive treatment still is > 170/105 mmHg when using home blood pressure measurements or 24-hour ambulatory blood pressure measurement.